(Reuters) - Denmark's Lundbeck got a fresh boost for its experimental drug Brintellix on Monday when a clinical trial showed benefits over another medicine called agomelatine that is often used when cheap generic pills fail. Lundbeck and its Japanese partner Takeda submitted the new antidepressant, which is also known as vortioxetine, for regulatory approval in the United States and Europe at the end of last year. In the latest study, Brintellix proved significantly more effective than agomelatine, which is sold as Valdoxan by private French drugmaker Servier, Lundbeck said. ...